




Filana Therapeutics INC

Rank 31 of 471

The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 177% points. The greatest weakness of Filana Therapeutics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 401%, being 156% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	211,226
Cost of Goods Sold	0
Intangible Assets	622
Liabilities, Current	7,063
Liabilities, Non-Current	232
Other Assets	122
Other Compr. Net Income	0
Other Expenses	68,032
Other Liabilities	0
Other Net Income	997
Other Revenues	2,777
Property and Equipment	22,864
Research and Development	0
Selling, General and Administrative Expense	11,988

Output Variable	Value in 1000 USD
Assets	234,834
Liabilities	7,295
Expenses	80,020
Revenues	2,777
Stockholders Equity	227,539
Net Income	-76,246
Comprehensive Net Income	-76,246
BaseVar	162,962
ECR before Limited Liability	347%
Economic Capital Ratio	401%